Lixisenatide is a short-acting, once-daily GLP-1 receptor agonist approved as Adlyxin for glycaemic control in adults with type 2 diabetes. It is not approved for weight management.

Established. Review the research and limitations before relying on this record.

Lixisenatide is an exendin-4-derived peptide agonist at the GLP-1 receptor. It increases glucose-dependent insulin release, suppresses glucagon when glucose is elevated, and slows gastric emptying. Its pronounced post-meal gastric-emptying effect and short exposure distinguish it from the longer-acting human-GLP-1 analogues.

The FDA label reports a mean terminal half-life of approximately three hours and apparent clearance near 35 L/h after repeated dosing in type 2 diabetes. It is eliminated by glomerular filtration followed by proteolytic degradation. Delayed gastric emptying can alter the timing of absorption of oral medicines.

FDA-approved as an adjunct to diet and exercise for glycaemic control in adults with type 2 diabetes. In ELIXA, 6,068 people with type 2 diabetes and a recent acute coronary syndrome were followed for a median 25 months; lixisenatide was non-inferior to placebo for major cardiovascular events but not superior. That establishes cardiovascular safety in a high-risk population, not cardiovascular benefit or a weight-management indication.

Common labelled adverse reactions include nausea, vomiting, headache, diarrhoea, dizziness and hypoglycaemia. Important warnings cover anaphylaxis, pancreatitis, hypoglycaemia with insulin or secretagogues, acute kidney injury from volume depletion, severe gastrointestinal reactions, gallbladder disease and aspiration risk during anaesthesia or deep sedation.

This is a source-backed summary, not a recommendation. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome. Availability, legal status and product quality differ by jurisdiction; consult a qualified clinician.